Core Viewpoint - The controversy surrounding the authenticity of collagen content in a product by Juzhi Biotechnology has sparked significant discussion, particularly regarding the testing methods used to measure collagen levels [1][2]. Group 1: Testing Methods and Controversy - The testing method used by Juzhi Biotechnology, known as the Biuret method, has been questioned for its reliability in complex cosmetic formulations, as it may yield inflated results due to interference from other ingredients [5][7]. - A blogger has raised concerns that the Biuret method cannot accurately distinguish between collagen and other peptide components, such as sodium polyglutamate, which could lead to misleading results [5][6]. - The blogger also highlighted discrepancies between the product versions sent for testing by Juzhi Biotechnology and their own submissions, indicating potential inconsistencies in the testing process [6]. Group 2: Regulatory Attention and Market Impact - The controversy has attracted regulatory scrutiny, with local market supervision authorities acknowledging the issue and beginning investigations [9][10]. - Following the controversy, the 1.0 version of the product has reportedly been removed from major e-commerce platforms, while the 2.0 version remains available for sale [10].

Core Viewpoint - The controversy surrounding the collagen content in the "可复美重组胶原蛋白肌御修护次抛精华" product has raised significant concerns regarding the accuracy of its labeling and the validity of the testing methods used to assess its ingredients [2][5]. Group 1: Product Testing and Claims - A beauty influencer claimed that the collagen content in the product was only 0.0177%, which is below the national standard minimum of 0.1% for non-trace ingredients [2]. - The influencer's testing method, HPLC, is not recognized by current industry standards, leading to questions about the reliability of the results [5]. - 可复美's internal tests reportedly show collagen content between 0.27% and 0.28%, which complies with the labeling regulations [5]. Group 2: Regulatory Compliance and Labeling - According to the "Cosmetic Labeling Management Measures," non-trace ingredients must be listed separately if they are present in amounts greater than or equal to 0.1% [5]. - 可复美 asserts that "soluble collagen" is listed seventh in the ingredient order, which aligns with regulatory requirements [5]. - The influencer's claim that the actual collagen content is 0.0177% raises concerns about potential false labeling practices [5]. Group 3: Market Impact - The product, known as "胶原棒," is a top-selling item for 可复美, with over 1 million units sold through a single link on its flagship store [5]. - The timing of the controversy, just before the "618" shopping festival, could lead to increased returns and cautious behavior from distributors [5].

Core Viewpoint - The controversy surrounding the product testing methods and results of Juzhibio has raised significant consumer trust issues, particularly affecting its KefuMei brand ahead of the critical 618 shopping festival [2][3] Group 1: Allegations and Responses - Beauty influencer "Big Mouth Doctor" has publicly questioned the testing methods used by Juzhibio, specifically the "biuret method," claiming it could lead to inflated results due to the presence of sodium polyglutamate in the products [2] - Juzhibio has denied the allegations and stated that they have commissioned a third-party organization for further testing [2] - The influencer has raised three key scientific questions regarding the presence of recombinant collagen in the products and the absence of glycine, a critical component [2] Group 2: Consumer Impact - The negative publicity has led to a noticeable decline in consumer trust towards KefuMei products, with many consumers expressing doubts in the comments section of major e-commerce platforms [2] - As the 618 shopping festival approaches, the potential impact on KefuMei's sales performance is significant, with concerns that consumer hesitation may persist until third-party test results are released [2][3] Group 3: Urgency for Resolution - The internal testing by Juzhibio was completed on May 24, but the results from the third-party testing have not yet been disclosed, leading to increased public scrutiny [3] - The need for authoritative testing results and clear explanations is critical for restoring consumer confidence and resolving the ongoing controversy [3]

Summary of the Conference Call for Juzi Biotechnology Company Overview - **Company**: Juzi Biotechnology - **Key Brands**: Kefu Mei and Keli Jin Industry Insights - **Market Trends**: The recombinant collagen market continues to show strong growth potential, with no signs of slowing down. The demand for products in this category remains robust, as evidenced by the high growth rates of key products and positive feedback from new product launches [4][10]. Core Points and Arguments - **Product Innovation**: Juzi Biotechnology is driving growth through product iterations, such as the upgrade of collagen peptide to version 2.0, and the introduction of new products like Focus Cream and Honey Repair Cream. These new products have received positive feedback from distribution channels and are expected to become new growth drivers [2][5]. - **Kefu Mei Brand Strengths**: Kefu Mei focuses on efficacy and safety, having established professional trust through medical device certification. The brand is expanding its product line into niche areas such as acne treatment and thermal injury repair, while also enhancing offline direct store presence to improve market performance [2][9]. - **Sales Performance**: Kefu Mei's collagen stick accounts for approximately 30% of total sales and continues to grow rapidly. The new customer acquisition rate is close to 50%, with a repurchase rate significantly higher than the industry average [2][12]. - **Keli Jin Brand Dynamics**: Keli Jin has achieved short-term growth through organizational restructuring and product line optimization. However, long-term growth may face challenges due to potential limitations in collagen technology for anti-aging effects [2][20]. - **Regulatory Challenges**: Sales of Class II medical device products are growing steadily, but the approval process for Class III medical devices is slow, with uncertain timelines for specific approvals despite receiving priority review qualifications for collagen fillers [2][21]. Financial Performance - **Revenue Growth**: Juzi Biotechnology has experienced rapid revenue and profit growth, although the sales expense ratio has increased. The company plans to control this ratio through product combination sales and customer referral strategies [6][7]. Marketing and Competitive Landscape - **Competitive Positioning**: Kefu Mei differentiates itself from competitors by emphasizing safety and efficacy. The brand has established a strong medical aesthetic image through partnerships with hospitals and medical institutions, contrasting with competitors that rely on celebrity endorsements [17][25]. - **Market Competition**: While other brands have launched collagen products, Kefu Mei's unique positioning and established trust in safety and efficacy mitigate significant competitive threats. The market is expanding collectively rather than through direct competition [25]. Product Strategy - **Product Development**: Kefu Mei's strategy includes launching successful single products and then expanding related skincare offerings. The brand also targets various consumer needs with different product forms [11][12]. - **New Product Launches**: The Focus Cream and Zhenyu Secret Repair Cream have distinct market positions, with the latter targeting a high-end consumer segment and addressing specific skin repair needs [18]. Future Outlook - **Growth Projections**: Kefu Mei is expected to achieve a growth rate of 40% to 50% in Q1 2025, with an annual performance forecast of 25% to 28%. The overall performance is anticipated to remain stable due to new product launches and marketing strategies [10][19]. Additional Considerations - **Consumer Sentiment**: Recent controversies regarding product ingredient content are not expected to significantly impact the company's fundamentals, as consumer recognition of product efficacy remains high [3][24]. - **Offline Expansion**: Kefu Mei has begun establishing offline direct stores, with plans to open 40 new locations in 2025. This strategy aims to enhance member interaction and improve market performance [22][23].

Core Viewpoint - The domestic medical beauty industry is facing significant scrutiny due to allegations regarding the quality and labeling of collagen products, particularly targeting the leading company, Giant Bio, and its flagship product, "Collagen Stick" [1][5][6]. Industry Overview - The controversy highlights the lack of national standards for the testing of recombinant collagen in cosmetics, leading to significant discrepancies in test results as companies rely on self-defined methods or pharmaceutical industry standards [5][6]. - The National Medical Products Administration has initiated the establishment of industry standards for recombinant collagen and its testing methods, with companies participating in the process [5]. Company-Specific Issues - Giant Bio's "Collagen Stick" was accused of having a collagen content of only 0.0177%, which is below the national cosmetic labeling requirement of 0.1% for non-trace additives, and the key amino acid glycine was reportedly not detected [6][8]. - In response to the allegations, Giant Bio issued a statement denying the claims, asserting that their products meet the required standards and have been approved by regulatory authorities [8]. Testing Method Discrepancies - The testing methods used by the parties involved differ significantly; the blogger employed a high-precision HPLC method, while Giant Bio referenced outdated national standards that have been criticized for their ineffectiveness in the current complex cosmetic landscape [9][10]. - The HPLC method is noted for its high sensitivity and ability to accurately quantify amino acids, while the methods referenced by Giant Bio have been deemed inadequate for testing collagen in cosmetics [10][15]. Market Impact - Following the allegations, Giant Bio's stock price fell over 8% on the Hong Kong Stock Exchange, closing down 4.04%, reflecting market concerns over the credibility of its products [8].

在皮肤健康管理领域，基底膜的重要性早已被学界广泛认知，它堪称皮肤的"地基"，维系着表皮与真皮间的稳固连 接。而作为基底膜核心支撑结构的IV型胶原蛋白，不仅主导皮肤屏障修护进程，更在痤疮、瘢痕增生等皮肤健康问题 上具有关键作用。 在全球化妆品科学领域不断追求创新突破的当下，合成生物学正成为驱动产业发展的核心力量。近期，ICIC2025国际 化妆品创新大会在上海圆满落幕，这场汇聚世界权威皮肤学专家的高规格盛会，聚焦前沿科技成果，为产业发展注入 新动能。作为全球重组胶原蛋白领导者，巨子生物携旗下品牌可复美深度参与大会，不仅举办《合成生物学驱动产业 发展新技术》学术交流分论坛，还成功召开「巨子生物独家专利重组IV型胶原蛋白」发布会，充分展现了以合成生物 学驱动产业创新的强劲实力。 学界洞见：合成生物学重塑皮肤健康管理新范式 巨子生物搭建起以生物活性成分为基础的合成生物学平台，成为全球首家实现量产并商业化生产重组胶原蛋白的企 业。依托前沿合成制备技术，企业突破性实现重组IV型胶原蛋白的研发与规模化量产，并在中国首次实现重组IV型胶 原蛋白与基底膜屏障完整性作用机制的系统性科学验证。大量实验数据证实了其褪红与修护双通路作 ...

Core Viewpoint - The controversy surrounding the skincare brand Kefu Mei, owned by Juzhi Biotechnology, has raised significant concerns about the authenticity of its flagship product, the recombinant collagen essence, which was alleged to contain only 0.0177% collagen, contradicting regulatory standards that require non-trace ingredients to exceed 0.1% [1][2][3] Company Summary - Juzhi Biotechnology, established in 2000, is a leading player in the recombinant collagen market in China, with a revenue growth from 900 million yuan in 2019 to 5.5 billion yuan in 2024, marking a more than fivefold increase [8] - The company reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2%, and a net profit of 2.062 billion yuan, up 42.1% [8] - Kefu Mei, the core brand of Juzhi Biotechnology, generated 4.54 billion yuan in revenue in 2024, reflecting a significant growth of 62.9% [9] Industry Summary - The recombinant collagen market in China was valued at 10.8 billion yuan in 2021 and is projected to surge to 219.38 billion yuan by 2030, with a compound annual growth rate of 44.93% [8] - The absence of industry standards for the collagen content in cosmetics has led to regulatory ambiguities, as highlighted by the ongoing controversy [7] - The recent scrutiny of Juzhi Biotechnology's products comes at a time when recombinant collagen is gaining popularity in the cosmetic industry, potentially replacing hyaluronic acid as a preferred ingredient [9]

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, the "Recombinant Collagen Essence," has raised significant concerns about its actual collagen content and potential false advertising, leading to a sharp decline in its stock price and questioning the company's marketing practices [1][3]. Group 1: Product Controversy - A report by the self-media "Big Mouth Doctor" claims that the actual recombinant collagen content in Juzhibio's "Recombinant Collagen Essence" is only 0.0177%, which is below the cosmetic labeling standard of 0.1% [2][3]. - The report also highlights the absence of glycine, a key structural component of collagen, challenging the product's technical authenticity [2]. - Juzhibio has denied these claims, asserting that internal tests show collagen content greater than 0.1% and questioning the validity of the testing methods used by the "Big Mouth Doctor" team [3]. Group 2: Financial Performance and Dependency - Juzhibio's revenue is heavily reliant on its skincare products, with 99.7% of revenue coming from this segment, while health products contribute only 0.3% [5]. - The "Recombinant Collagen" and "Keli Jin" brands account for over 90% of the company's revenue, indicating a significant dependency on these two brands [6][7]. - In 2024, Juzhibio's sales and distribution expenses are projected to be 2.008 billion yuan, while R&D expenses are only 106 million yuan, highlighting a 19-fold disparity [7]. Group 3: Market Impact - Following the allegations, Juzhibio's stock price fell by 8% after the market opened on May 26 [3]. - The affected product has been removed from all sales channels, including major platforms like Taobao, Douyin, and JD [3]. - If consumer backlash leads to collective lawsuits or mass returns, it could severely impact the company's sales performance during key promotional periods, jeopardizing its annual revenue growth targets [6].

Group 1: Consumer Trust and Brand Management - Consumer trust and preference are vital market resources for consumer-facing companies, reflecting their brand building and emergency strategies [1] - The integration of consumer brands with company operations has intensified, making public sentiment management crucial for brand reputation [1] - A quantitative scoring mechanism, the "Consumer Sentiment Warning Index," has been developed to evaluate companies' responses to public sentiment crises [1] Group 2: Company Case Study - Giant Biological - Giant Biological's core brand, Kefu Mei, is facing controversy over the collagen content in its products, following allegations of potential fraud by a beauty influencer [2][5] - The influencer's testing revealed a collagen content of only 0.0177%, raising questions about the product's integrity [2] - Giant Biological responded by asserting that their internal testing showed collagen levels exceeding 0.1%, but the lack of authoritative national standards for collagen testing has led to ongoing disputes [6][5] Group 3: Industry Implications - The controversy highlights the need for established industry standards regarding the safety and content of cosmetic ingredients, particularly recombinant collagen [6] - As a leading player in the industry, Giant Biological must address public concerns and enhance its long-term product quality monitoring systems [7] - The incident underscores the broader issue of ingredient safety and transparency in the rapidly evolving beauty sector [6] Group 4: Company Case Study - Perrier - Perrier, produced by Nestlé, is under investigation for consumer fraud related to water source contamination and improper treatment methods [7][8] - The investigation revealed that Perrier's production methods may not comply with European regulations for natural mineral water, raising significant health concerns [7] - Nestlé has reiterated its commitment to food safety and the integrity of its products, emphasizing collaboration with local stakeholders to protect water resources [10] Group 5: Market Impact and Brand Reputation - The scandal poses a severe threat to Perrier's brand image, which has been built on high-end positioning and quality [11] - Consumer trust in Perrier has been significantly undermined, prompting a reevaluation of their product choices [11] - To regain consumer confidence, Perrier must conduct thorough investigations, ensure transparency, and strengthen supply chain management [11]

Core Viewpoint - The controversy surrounding the alleged fraud of the collagen essence product from Giant Biological (02367.HK) continues to escalate, with significant focus on the testing methods used to validate the claims made by Dr. Hao Yu, who has accused the product of containing only 0.0177% of recombinant collagen [1][3][5]. Group 1: Allegations and Responses - Dr. Hao Yu claims that the key component "glycine" is missing from the collagen essence, raising doubts about the product's authenticity [3]. - Giant Biological has issued a statement denying the allegations, asserting that their internal testing shows collagen content greater than 0.1%, contradicting Dr. Hao's findings [5][6]. - The company emphasizes adherence to regulatory standards and claims that all products undergo rigorous quality control processes [6][8]. Group 2: Testing Methods - The testing methods used by Dr. Hao Yu have been questioned by Giant Biological, which argues that the methods are not recognized by industry standards and lack proper validation [1][10]. - Dr. Hao Yu defends his use of high-precision HPLC amino acid quantification method, stating it is widely accepted internationally and has been validated for accuracy [1][10]. - Giant Biological has committed to obtaining third-party testing results to further validate their claims, indicating that they are awaiting the results from multiple authoritative testing agencies [2][8]. Group 3: Industry Context - The lack of established industry standards for measuring recombinant collagen content in cosmetics has been highlighted as a significant issue in this controversy [10]. - Dr. Hao Yu's background in organic chemistry and experience in the cosmetics industry lend credibility to his claims, although he asserts that there is no competitive motive behind his allegations [11][14]. - The ongoing debate raises questions about product quality and consumer trust in the cosmetic industry, particularly regarding the accuracy of ingredient labeling [16].